Who
Sandip Kapadia
Director
Company insider
Files Form 4 as: Director, Passage Bio; Chief Financial Officer, Harmony Biosciences Holdings; CFO and Treasurer, Intercept Pharmaceuticals.
In numbers
- Trades disclosed
- 97
- Buys
- 1
- Sells
- 13
- Bought
- $90K
- Sold
- $5.1M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Jul 2016
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Sold | $139K3,746 at $37.15 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Sold | $139K3,746 at $37.15 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code M | —4,725 at $0.00 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,725 at $0.00 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code F | $94K2,553 at $36.82 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,725 at $0.00 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code M | —4,725 at $0.00 | filing |
| 25 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code F | $94K2,553 at $36.82 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code M | —3,813 at $0.00 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code F | $82K2,239 at $36.82 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,813 at $0.00 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,813 at $0.00 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code M | —3,813 at $0.00 | filing |
| 24 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences HoldingsPharmaceuticals | SEC FORM 4 Code F | $82K2,239 at $36.82 | filing |
| 22 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —42,600 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —42,600 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
News
Harmony Biosciences (NASDAQ:HRMY) Given "Buy" Rating at Needham & Company LLCHRMY · themarketsdaily.com · 20 Oct 2026Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – Here's What HappenedHRMY · tickerreport.com · 14 Oct 2026Lipocine (NASDAQ:LPCN) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head AnalysisHRMY · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Sandip Kapadia; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.